MBM Wealth Consultants LLC Purchases New Shares in DexCom, Inc. (NASDAQ:DXCM)

MBM Wealth Consultants LLC acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 5,922 shares of the medical device company’s stock, valued at approximately $465,000.

Several other hedge funds have also modified their holdings of DXCM. Dimensional Fund Advisors LP boosted its position in DexCom by 41.3% during the second quarter. Dimensional Fund Advisors LP now owns 919,650 shares of the medical device company’s stock worth $104,282,000 after purchasing an additional 268,802 shares in the last quarter. Pacer Advisors Inc. lifted its position in shares of DexCom by 10.9% during the 2nd quarter. Pacer Advisors Inc. now owns 49,319 shares of the medical device company’s stock valued at $5,592,000 after buying an additional 4,831 shares in the last quarter. Steel Grove Capital Advisors LLC grew its stake in DexCom by 11.8% in the 2nd quarter. Steel Grove Capital Advisors LLC now owns 2,850 shares of the medical device company’s stock valued at $323,000 after acquiring an additional 300 shares during the period. Public Sector Pension Investment Board increased its holdings in DexCom by 96.3% in the 2nd quarter. Public Sector Pension Investment Board now owns 16,842 shares of the medical device company’s stock worth $1,910,000 after acquiring an additional 8,261 shares in the last quarter. Finally, Xponance Inc. increased its holdings in DexCom by 2.5% in the 2nd quarter. Xponance Inc. now owns 89,460 shares of the medical device company’s stock worth $10,143,000 after acquiring an additional 2,141 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on DXCM shares. Sanford C. Bernstein raised their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Canaccord Genuity Group lifted their target price on shares of DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Citigroup increased their target price on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Raymond James cut their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Five research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $99.29.

DexCom Stock Up 2.3 %

Shares of NASDAQ DXCM opened at $86.32 on Wednesday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The business’s 50 day moving average is $78.46 and its two-hundred day moving average is $77.56. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The firm has a market cap of $33.72 billion, a price-to-earnings ratio of 51.69, a PEG ratio of 2.21 and a beta of 1.12.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.